Current version snapshot

FDA-approved↗↗Gastrointestinal↗

Current · version 3: Plecanatide↗

Related names recorded in this version: Trulance↗

A guanylate cyclase-C agonist approved by FDA as Trulance for chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked the Trulance label, and added the Drugs@FDA approval record. 12

What this version reported

Four large 12-week randomized, placebo-controlled trials described in the label support its uses. The label carries a boxed warning about serious dehydration in children.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗

Reader guide in this version

Key takeaway

Plecanatide is a lab-made analogue of uroguanylin, a natural gut hormone, and is the active ingredient in Trulance.1,2 It is FDA-approved for chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.1 Its approvals rest on four large 12-week randomized, placebo-controlled trials of about 700 to 900 adults each described in the label.1 The label carries a boxed warning about serious dehydration in children: it is contraindicated below age 6 and should be avoided from age 6 to under 18.1

At a glance

What it is
A guanylate cyclase-C agonist and structural analogue of uroguanylin that the label says acts locally on the lining of the intestine.1
FDA status
FDA-approved. Drugs@FDA lists Trulance with an original approval date of January 19, 2017. The label carries a boxed warning about serious dehydration in children.1,2
Human evidence
Four large 12-week randomized, double-blind, placebo-controlled trials in adults, described in the label.1
Evidence strength
Large randomized human trials

What is plecanatide?

Plecanatide is a lab-made peptide that the label describes as a structural analogue of human uroguanylin, a hormone made in the gut.1

In the United States it is the active ingredient of Trulance, from Salix, according to Drugs@FDA.2

How does plecanatide work?

The label states that plecanatide and its active breakdown product activate guanylate cyclase-C on the intestinal lining, increasing a signalling molecule, cGMP, which draws chloride, bicarbonate and fluid into the intestine and speeds transit.1

The label also states that in an animal model of intestinal pain, plecanatide reduced a measure of abdominal pain.1

What do human studies show?

The label describes two 12-week randomized, double-blind, placebo-controlled trials in adults with chronic idiopathic constipation, which randomized 905 and 870 participants. Responders, defined by more complete bowel movements in most weeks, made up 21% of the plecanatide groups in both trials, compared with 10% and 13% on placebo.1

Two further 12-week trials in adults with irritable bowel syndrome with constipation included 699 and 754 participants, and measured both abdominal pain and bowel movements.1

Diarrhea was the most common adverse reaction across the four trials, and severe diarrhea was reported in 0.6% of participants, according to the label.1

What the evidence base contains

  • Large randomized human trial Two 12-week randomized, double-blind, placebo-controlled trials in chronic idiopathic constipation that randomized 905 and 870 adults.1
  • Large randomized human trial Two 12-week randomized, double-blind, placebo-controlled trials in irritable bowel syndrome with constipation in which 699 and 754 adults received plecanatide or placebo.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is plecanatide FDA-approved?

Yes. Drugs@FDA lists Trulance, application NDA208745, with an original approval date of January 19, 2017.2

The Trulance label cited here (DailyMed SPL version 15, published April 5, 2024) states that it is indicated in adults for chronic idiopathic constipation and irritable bowel syndrome with constipation.1

The label carries a boxed warning: plecanatide is contraindicated in children younger than 6, because a single exposure caused deaths from dehydration in young mice, and should be avoided from age 6 to under 18. The label states that its safety and effectiveness below age 18 have not been established.1

The label also states that it is contraindicated in people with known or suspected mechanical blockage of the gut.1

Timeline

  1. FDA approves Trulance, according to Drugs@FDA.2
  2. DailyMed publishes the Trulance label version cited on this page.1

What is still unknown?

Its safety and effectiveness in people younger than 18, which the label says have not been established.1

Its long-term effects: the label’s main trials lasted 12 weeks.1

Sources for this version

  1. 1
    TRULANCE (plecanatide) tablet · SPL version 15 · published 2024-04-05 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA208745 · original submission status AP · 2017-01-19 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026